Uruguay Drug Patents

« Back to Dashboard

Drug Patents in Uruguay and US Equivalents

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Patent Number	Estimated Expiration	Equivalent US Patent	US Expiry Date	Generic Name	US Applicant	US Tradename
25004		6294540	2018-11-14	abacavir sulfate	Viiv Hlthcare	ZIAGEN
25004		6294540	2018-11-14	abacavir sulfate; lamivudine	Viiv Hlthcare	EPZICOM
25004		6294540	2018-11-14	abacavir sulfate; lamivudine; zidovudine	Viiv Hlthcare	TRIZIVIR
25030		5968895	2016-12-11	abarelix	Speciality European	PLENAXIS
25030		6180608	2016-12-11	abarelix	Speciality European	PLENAXIS
25030		6699833	2016-12-11	abarelix	Speciality European	PLENAXIS
25113		6194429	2018-07-23	alatrofloxacin mesylate	Pfizer	TROVAN PRESERVATIVE FREE

Uruguay Biopharmaceutical Patent Landscape: Key Insights

Last updated: February 14, 2026

Patentability Criteria

Uruguay's patent law, aligned with regional standards, requires biopharmaceutical inventions to meet novelty, inventive step, and industrial applicability. Specific to biopharmaceuticals:

• Novelty: Must not be disclosed publicly prior to filing. Public disclosures, including publications or public use in Uruguay, invalidate the novelty claim.
• Inventive Step: The invention cannot be obvious to persons skilled in the field, considering prior art, which can include international publications and existing patents.
• Industrial Applicability: The invention should be capable of practical application, including manufacturing or use, in Uruguay.

Exclusions and Limitations

• Discoveries, scientific theories, or mere data collections do not qualify.
• Methods of medical treatment and surgery are explicitly excluded from patent protection under Uruguayan law, aligning with international standards.
• Naturally occurring substances and biological materials are not patentable unless modified or isolated sufficiently to meet inventive criteria.

Patent Enforcement

• Legal Framework: Uruguay’s legal system permits patent holders to enforce rights via administrative actions and litigation, with the possibility of injunctions, damages, and licensing agreements.
• Opposition and Invalidity: Post-grant opposition is available within prompt periods (typically six months), allowing third parties to challenge patent validity based on lack of novelty, inventive step, or exclusions.
• Challenges: Enforcement can encounter challenges due to the limited scope of patent protection for biological materials, and the focus on method claims over product claims.

Scope of Patent Claims

• Product Claims: Cover isolated biological molecules, derivatives, or formulations; these are generally granted if they demonstrate novelty and inventive activity.
• Process Claims: Claiming specific methods to produce or use biopharmaceutical substances are permissible, provided they are innovative and non-obvious.
• Use Claims: Use of known compounds for new therapeutic indications may be patentable if supported by inventive steps and sufficient clinical data.
• Claim Drafting: Claims should be specific to ensure enforceability; broad claims risk invalidity or rejection due to overlap with prior art.

Regional and International Considerations

• Uruguay is a signatory of the Patent Cooperation Treaty (PCT), allowing applicants to file internationally through a single application for subsequent national phase entry.
• Compatibility with regional patent standards influences scope and enforcement potential; consulting local experts for strategic drafting is recommended.

Recent Trends & Policy Developments

• Uruguayan patent examiners increasingly scrutinize biopharmaceutical patent applications for clear, detailed claims, especially regarding biological and chemical modifications.
• Amendments to patent laws may expand or restrict patentability and enforceability; ongoing legal reforms should be monitored.

Key Takeaways

• Biopharmaceutical patents in Uruguay require strict compliance with novelty, inventive step, and industrial applicability.
• Methods of treatment are excluded from patentability.
• Product claims, when properly supported, form the core of enforceable rights.
• Opposition proceedings serve as a tool to challenge weak patent rights post-grant.
• Strategic claim drafting and understanding of international agreements optimize patent scope and enforceability.

FAQs

1. Can biologic molecules be patented in Uruguay?
   Yes, if they are sufficiently isolated, modified, or characterized to meet patent criteria, avoiding natural substance exclusions.

2. Are method-of-treatment patents enforceable?
   No, such methods are explicitly excluded from patent protection in Uruguay.

3. What are common grounds for patent opposition?
   Lack of novelty, inventive step, or violations of exclusions, such as natural material discoveries.

4. How does Uruguay treat patents for traditional knowledge or natural substances?
   They are generally not patentable unless significantly modified or characterized beyond mere discovery.

5. What strategic considerations are key for biopharmaceutical patent drafting?
   Claims should be specific, supported by detailed data, and balanced between broad protection and enforceability.

Sources

1. Uruguay Patent Law, Law No. 16.463 (2003).
2. World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT).
3. Uruguayan Patent Office (DINAPI) guidelines.
4. International Patent Classification (IPC), Volume 2.
5. Regional patent standards (ARIPO, EPO equivalents).